Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2017-02-15Clinical Trial Update: To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis [Phase 4]
A Phase 4 clinical trial is evaluating combination therapy versus monotherapy for pulmonary arterial hypertension in systemic sclerosis, wit…
-
EMA safety_alert · 2017-02-14EMA reviewing safety of Uptravi for pulmonary arterial hypertension (updated)*
EMA is reviewing safety information for Uptravi (tracleer? actually Uptravi is selexipag) in pulmonary arterial hypertension and providing u…
-
FDA approval · 2017-01-24FDA Approved: ORENITRAM — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for ORENITRAM (treprostinil) filed by United Therapeutics Corporation. The approval represents a…
-
FDA approval · 2017-01-17FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for ADEMPAS (riociguat) from Bayer HealthCare Pharmaceuticals Inc., approving a change to the drug's…
-
FDA approval · 2016-12-16FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for Tracleer (bosentan) by Actelion Pharmaceuticals US. The approval updates the drug’s labeling and…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-12-15FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) from Gilead Sciences, Inc., resulting in changes to the product label…
-
CLINICAL_TRIALS trial_result · 2016-12-09Clinical Trial Update: Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension [Phase 3]
Phase 3 trial results for Epoprostenol for Injection in patients with pulmonary arterial hypertension have been posted. The study was sponso…
-
FDA label_change · 2016-11-22FDA Approved: REVATIO — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for REVATIO (sildenafil citrate) submitted by Viatris Specialty LLC.
-
CLINICAL_TRIALS research · 2016-11-22Clinical Trial Update: The Screening and Analysis of Plasma Biomarkers in Irreversible PAH-CHD
A completed clinical trial update reporting on screening and analysis of plasma biomarkers in irreversible pulmonary arterial hypertension a…
-
CLINICAL_TRIALS trial_result · 2016-11-17Clinical Trial Update: Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin)
This clinical trial update reports on right ventricular performance in patients with pulmonary arterial hypertension treated with rapid-dose…
-
CLINICAL_TRIALS withdrawal · 2016-11-15Clinical Trial Update: FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan [NA]
A clinical trial evaluating FDG uptake and lung blood flow in pulmonary arterial hypertension before and after treatment with ambrisentan ha…
-
CLINICAL_TRIALS trial_result · 2016-10-27Clinical Trial Update: A Pharmacokinetic Substudy of the TDE-PH-304 Protocol [Phase 3]
A pharmacokinetic substudy embedded in a Phase 3 trial of TDE-PH-304 in pulmonary arterial hypertension has completed with results posted.
-
FDA approval · 2016-10-21FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for OPSUMIT (macitentan) from Actelion Pharmaceuticals US, Inc. This action represents an update…
-
CLINICAL_TRIALS trial_result · 2016-10-21Clinical Trial Update: To Compare the Pharmacokinetics of Traclear 62.5 mg Tablets and HGP1206 125mg 1 Tablet in Healthy Male Volunteers [Phase 1]
Phase 1 pharmacokinetic comparison of Traclear 62.5 mg tablets and HGP1206 125 mg in healthy male volunteers has been completed.
-
FDA approval · 2016-10-20FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA has approved a supplemental application for TRACLEER (bosentan) from Actelion Pharmaceuticals US, Inc. to modify or expand its labeling.…
-
FDA approval · 2016-10-17FDA Approved: SILDENAFIL — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for sildenafil (generic) from Amneal Pharmaceuticals of New York LLC under an ANDA. The approval all…
-
CLINICAL_TRIALS trial_result · 2016-10-05Clinical Trial Update: FK506 (Tacrolimus) in Pulmonary Arterial Hypertension [Phase 2]
Phase 2 trial results for tacrolimus (FK506) in pulmonary arterial hypertension have been completed and results posted.
-
FDA approval · 2016-10-04FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for ADEMPAS (riociguat) submitted by Bayer HealthCare Pharmaceuticals Inc., resulting in an updated …
-
CLINICAL_TRIALS trial_result · 2016-09-19Clinical Trial Update: Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. [Phase 2]
Phase 2 study of inhaled GeNOsyl for pulmonary arterial hypertension and pulmonary hypertension due to idiopathic pulmonary fibrosis has com…
-
CLINICAL_TRIALS trial_result · 2016-08-31Clinical Trial Update: Feasibility of Slow-paced Respiration Therapy for Treatment of a Symptom Cluster in Pulmonary Arterial Hypertension [Phase 1, Phase 2]
A completed Phase 1/2 study evaluating the feasibility of slow-paced respiration therapy for managing symptoms in pulmonary arterial hyperte…
-
CLINICAL_TRIALS trial_result · 2016-08-31Clinical Trial Update: Contribution of Echocardiography to Prognostic Evaluation of Pulmonary Arterial Hypertension
A clinical trial investigating how echocardiography can improve prognostic evaluation in pulmonary arterial hypertension has completed.
-
CLINICAL_TRIALS trial_result · 2016-08-30Clinical Trial Update: Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585 [Phase 1]
Phase 1 study update reporting completion of single- and multiple-ascending-dose pharmacology evaluation of KAR5585 in pulmonary arterial hy…
-
CLINICAL_TRIALS trial_result · 2016-08-24Clinical Trial Update: Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) [Phase 1]
Phase 1 study evaluating dosing of sorafenib in patients with pulmonary arterial hypertension has been completed.
-
CLINICAL_TRIALS trial_result · 2016-08-15Clinical Trial Update: BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology [Phase 4]
Phase 4 clinical trial assessing bosentan (Tracleer) in patients with pulmonary arterial hypertension related to Eisenmenger physiology has …
-
CLINICAL_TRIALS trial_result · 2016-08-12Clinical Trial Update: Effect of Short-term Oxygen During CPET in Pulmonary Hypertension [Phase 2]
A Phase 2 trial evaluating the effect of short-term oxygen during CPET in pulmonary hypertension has completed.